# A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.

> **NCT03966651** · PHASE1 · COMPLETED · sponsor: **Institut Claudius Regaud** · enrollment: 1 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** PRRT with 177Lu-DOTATATE

## Key facts

- **NCT ID:** NCT03966651
- **Lead sponsor:** Institut Claudius Regaud
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-17
- **Primary completion:** 2024-08-08
- **Final completion:** 2024-08-30
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03966651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03966651, "A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT03966651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*